Glioblastoma
Conditions
Keywords
glioblastoma, tumor electric fields treatment
Brief summary
This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.
Detailed description
Subjects who have previously completed radiotherapy and at least two cycles of chemotherapy with imaging or pathological evidence of tumor recurrence will receive Tumor Electric Fields Treatment System. The main objective is to evaluate the safety of applying the Tumor Electric Fields Treatment System to subjects with recurrent GBM.
Interventions
DEVICETumor Electric Fields Treatment System
Patients wear two pairs of electrodes on the head for 19-22 hours a day. Each patient is required to wear the device as long as possible and not less than 6 months. The treatment has a two-day break for every four weeks.
Sponsors
Hunan An Tai Kang Cheng Biotechnology Co., Ltd
Xiangya Hospital of Central South University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with pathological diagnosis of glioblastoma at first surgery (WHO Grade IV, supratentorial location); * Age between 18 and 65 years, male or female; * Previously completed radiotherapy and at least two cycles of chemotherapy; * With imaging or pathological evidence of tumor recurrence; * Karnofsky performance score (KPS) score ≥ 70 before intervention; * With a life expectancy more than 3 months; * Adopted effective contraceptive measures at child-bearing age; * Provided written informed consent.
Exclusion criteria
* Patients unwilling to use the equipment ≥ 18h per day; * With poor compliance or live too far from the research center, who cannot keep regular follow-up or adjust the electrode position of the treatment equipment, and who refuse to receive follow-up to terminal survival; * With poor healing of scalp wound, poor scalp condition, large skull defect or other cases where electrodes are not suitable for wearing; * Within 3 months from radiotherapy; * Within 4 weeks from the last cycle of chemotherapy; * Within 4 weeks from surgery for recurrence; * Participated in other clinical trials. * Pregnant; * Epilepsy symptoms not effectively controlled; * Blood and biochemical indicators in the following range: A. Liver function impairment: AST or ALT \> 3 times the upper limit of normal; B. Total bilirubin\> upper limit of normal value; C. Renal impairment: serum creatinine\>1.7mg /dL (\>150 mol/L); D. Coagulopathy: PT or APTT \>1.5 times normal; E. Platelets counts \< 100x10\^9/L; F. Absolute neutrophils count \< 1x10\^9/L; G. Hemoglobin \< 100g/L; * With severe infectious diseases, such as acute severe infection and HIV positive; * Other conditions, such as an implanted cardiac pacemaker or deep brain stimulator, severe intracranial edema, increased intracranial pressure resulting in midline shift\>5mm, clinically significant papilledema, or reduced level of consciousness, allergy to conductive coupling agent, gel, and other serious life-threatening diseases. * Other circumstances considered inappropriate to participate in the research by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The treatment-related adverse events | 12 months | Number of patients who experienced a treatment-related adverse event. |
| Time to Progression | 12 months | Time to progression of patients with recurrent glioblastoma. |
| Overall Survival Rate | 12 months | Number of patients alive at 12 months. |
Countries
China
Contacts
Primary ContactZhixiong Liu, M.D.
Outcome results
None listed